secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001937653-25-000047
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks posts Q2 net income of $2.3M on revenue of $48.7M; cash runway into 2H-2027
--------------------------------------------------------------------------------

- Revenue of $48.7M in Q2 2025 vs $19.2M in Q2 2024, driven by $20M BeOne milestone and $7.5M BMS license option.
- Net income of $2.3M compared to net loss of $37.7M in Q2 2024; R&D expenses $34.4M, G&A $15.0M.
- Cash resources $333.4M as of June 30, 2025, projected to fund operations into 2H-2027 with anticipated milestones.
- FDA cleared IND for ZW251 (GPC3-targeting ADC); Phase 1 planned for 2025, joining ZW171 and ZW191 in clinic.
- Jazz reported Ziihera net sales of $5.5M in Q2; conditional EU approval for HER2+ BTC and China approval noted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765325000047/0001937653-25-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765325000047/zyme-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001937653-25-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer